

554, 153

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number
WO 2004/107863 A1

(51) International Patent Classification⁷: **A01N 43/58**,
43/60, A61K 31/495, 31/50, C07D 471/00, 487/00,
491/00, 495/00, 497/00

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(21) International Application Number:
PCT/US2004/013778

(22) International Filing Date: 3 May 2004 (03.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/468,073 5 May 2003 (05.05.2003) US

(71) Applicant (for all designated States except US): **NEURO-
GEN CORPORATION** [US/US]; Patent Department, 35
Northeast Industrial Road, Branford, CT 06405 (US).

(71) Applicants and

(72) Inventors: **XU, Yuellian** [CN/US]; 140 Mill St., Apt. 854,
East Haven, CT 06512 (US). **HAN, Bingsong** [CN/US];
905 Mix Ave., Apt. 3G, Hamden, CT 06504 (US). **XIE,
Linghong** [US/US]; 136 Renee's Way, Guilford, CT 06437
(US).

(74) Agents: **KADLECEK, Ann et al.**; Neurogen Corporation,
35 Northeast Industrial Road, Branford, CT 06405 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)


— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **SUBSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIG-
ANDS**



(I)

(57) Abstract: Compounds of Formula (I) are provided, as are methods for their prepa-
ration. The variables Z₁, Z₂, Z₃, R₄, R₅, R₆, R₇, R₈, and Ar in the above Formula are
defined herein. Such compounds may be used to modulate ligand binding to GABA_A
receptors *in vivo* or *in vitro*, and are particularly useful in the treatment of a variety of
central nervous system (CNS) disorders in humans, domesticated companion animals,
and livestock animals. Compounds provided herein may be administered alone or in
combination with one or more other CNS agents to potentiate the effects of the other
CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are

provided, as are methods for using such ligands for detecting GABA_A receptors (e.g., receptor localization studies).

WO 2004/107863 A1